In sum, comorbid PTSD and respiratory illness continue to burden WTC responders over a decade post disaster, despite our pharmaceutical and psychotherapeutic efforts. Mind-body treatments have demonstrated promise for reducing both PTSD and respiratory symptoms, and potential biological markers underlying these conditions;however no randomized control trial (RCT) has evaluated this treatment approach among patients with comorbid PTSD and respiratory illness. The proposed study will be the first RCT to evaluate a novel mind-body treatment among WTC responders with these comorbidities, and thus, it will have important implications for health care costs, quality of life and functioning, morbidity and possibly mortality.
|Kosiba, Jesse D; Gonzalez, Adam; O'Cleirigh, Conall et al. (2014) Medication Adherence and HIV Symptom Distress in Relation to Panic Disorder Among HIV-Positive Adults Managing Opioid Dependence. Cognit Ther Res 38:458-464|